Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Researchers looked at the cases of 537 babies in England and Scotland who were admitted to hospital with severe respiratory disease.

A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out on the NHS in England this autumn. Experts say the drug will give thousands ...